Cargando…
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140485/ https://www.ncbi.nlm.nih.gov/pubmed/21799767 http://dx.doi.org/10.1371/journal.pone.0022019 |
_version_ | 1782208562937724928 |
---|---|
author | Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi García-Lerma, J. Gerardo Heneine, Walid |
author_facet | Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi García-Lerma, J. Gerardo Heneine, Walid |
author_sort | Hoffmann, Dieter |
collection | PubMed |
description | Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive “Amp-RT” assay with a newly-developed real-time PCR format to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine (NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings. |
format | Online Article Text |
id | pubmed-3140485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31404852011-07-28 Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi García-Lerma, J. Gerardo Heneine, Walid PLoS One Research Article Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive “Amp-RT” assay with a newly-developed real-time PCR format to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine (NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings. Public Library of Science 2011-07-20 /pmc/articles/PMC3140485/ /pubmed/21799767 http://dx.doi.org/10.1371/journal.pone.0022019 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi García-Lerma, J. Gerardo Heneine, Walid Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title | Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title_full | Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title_fullStr | Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title_full_unstemmed | Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title_short | Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing |
title_sort | measuring enzymatic hiv-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to hiv-1 drug-resistance testing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140485/ https://www.ncbi.nlm.nih.gov/pubmed/21799767 http://dx.doi.org/10.1371/journal.pone.0022019 |
work_keys_str_mv | AT hoffmanndieter measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT garciaalbertd measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT harriganprichard measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT johnstoniancd measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT nakasonetadashi measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT garcialermajgerardo measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting AT heneinewalid measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting |